PDCD1 and neoplasm: Subgroups were analyzed for differences between groups for different treatment schedules and tumor types, respectively, and their results revealed that (a) there were no statistically significant differences between the experimental group compared with the control arm for different combination regimens (p = 0.343), and (b) there was a statistically significant difference among the different tumor types in the combination group compared to anti-PD-1/PD-L1 (p < 0.001).